Focus: Cognixion is a neurotechnology biotech focused on brain-computer interface (BCI) solutions for neurological conditions like ALS. The company operates as a pre-revenue stage developer with a small, technical-focused team.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Best suited for risk-tolerant early-stage technologists seeking co-founder-level impact in neurotechnology, not for stability-seeking career builders.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cognixion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cognixion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo